Figure 1



Vessel 1
Vessel 2
Vessel 3
Vessel 4
Vessel 5
Vessel 6
% Dissolution
0
10
20
30
40
50
60
70
80
Time (minutes)
0
50
100
150
200

Figure 2



% Dissolution
0
10
20
30
40
50
60
70
80
Time (minutes)
0
20
40
60
80
100
120
140

Figure 3



stomach
small intestine
colon
pH
time (h)
8
7
6
5
4
3
2
1
0
2
4
6
8
10
12
14
16
18

Figure 4



% Dissolution
0
20
40
60
80
100
0
5
10
15
20
Time (hours)
Batch A
Standard (=105.2% released)

Figure 5



% Dissolution
0
10
20
30
40
50
60
70
80
90
0
5
10
15
20
Time (hours)
Batch B
Standard (=34.2% released)

Figure 6



Relative fluorescence
1
0.8
0.6
0.4
0.2
0
0
10
20
30
40
50
60
70
80
90
Temperature [°C]
A
B
C
D
E
F

Figure 7



Calculated luminal [anti-TNF ICVD] in cynomolgus monkey gastrointestinal tract sections
M234
M236
M238
Adalimumab trough
Infliximab trough
[anti-TNF ICVD], μM
10000
1000
100
10
1
0.1
0.01
Stomach
Duodenum
Jejunum
Ileum
Caecum
Upper colon
Lower colon

Figure 8



Total % recovery of anti-TNF ICVD from cynomolgus monkey gastrointestinal tracts
% anti-TNF ICVD recovered
100
80
60
40
20
0
M234
M236
M238

Figure 9



Humira competition ELISA OD450 data
8h
12h
20h
24h
36h
Pre-dose
Plate 1, Humira only control
Plate 2, Humira only control
ELISA assay signal OD450
0.0
0.5
1.0
1.5
2.0
2.5
100
1000
10000
Faecal supernatant dilution (fold)

Figure 10



anti-TNF ICVD concentration
in pooled cynomolgus monkey faeces
[anti-TNF ICVD] µM
0
2
4
6
8
12
20
24
Time, post dose (Hour)

Figure 11




Calculated anti-TNF ICVD recovered from pooled cynomolgus monkey faeces
anti-TNF ICVD µg
3000
2000
1000
0
8
12
20
24
Time, post dose (Hour)

Figure 12


% Released
100
90
80
70
60
50
40
30
20
10
0
0
1
2
3
4
5
6
Time (hrs)
Spray dried
Lyophilised